Table 4. Univariate Cox proportional hazards regression analysis for disease-free survival (DFS) and cancer-specific survival (CSS) in patients with laryngeal squamous cell cancer (LSCC).
| Characteristics | DFS | P | CSS | P |
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age (years) | 0.135 | 0.007 | ||
| <60 | 1.000 | 1.000 | ||
| ≥60 | 1.191 (0.947-1.499) | 1.465 (1.111-1.932) | ||
| Gender | 0.076 | 0.125 | ||
| Female | 1.000 | 1.000 | ||
| Male | 2.800 (0.898-8.733) | 2.975 (0.739-11.976) | ||
| Smoking history | 0.153 | 0.760 | ||
| NO | 1.000 | 1.000 | ||
| YES | 1.202 (0.934-1.546) | 1.047 (0.780-1.405) | ||
| Drinking history | 0.113 | 0.297 | ||
| NO | 1.000 | 1.000 | ||
| YES | 1.206 (0.957-1.519) | 1.158 (0.879-1.524) | ||
| Tumor subsite | <0.001 | <0.001 | ||
| Glottic & Subglottic | 1.000 | 1.000 | ||
| Supraglottic | 2.196 (1.730-2.789) | 2.215 (1.672-2.935) | ||
| Differentiation grade | 0.014 | 0.234 | ||
| Well & moderate | 1.000 | 1.000 | ||
| Poor | 1.878 (1.133-3.110) | 1.471 (0.779-2.780) | ||
| Tumor stage | <0.001 | <0.001 | ||
| T1-T2 | 1.000 | 1.000 | ||
| T3-T4 | 2.794 (2.220-3.516) | 2.737 (2.081-3.599) | ||
| Lymph node stage | <0.001 | <0.001 | ||
| N0 | 1.000 | 1.000 | ||
| N+ | 3.052 (2.316-4.022) | 2.880 (2.086-3.976) | ||
| Neutrophils (×109/L) | 0.248 | 0.567 | ||
| <3.20 | 1.000 | 1.000 | ||
| 3.20-4.30 | 1.154 (0.868-1.535) | 1.079 (0.770-1.513) | ||
| >4.30 | 1.271 (0.959-1.685) | 1.196 (0.858-1.668) | ||
| Platelets (×109/L) | 0.149 | 0.642 | ||
| <157.00 | 1.000 | 1.000 | ||
| 157.00-200.00 | 0.829 (0.623-1.104) | 0.883 (0.631-1.235) | ||
| > 200.00 | 1.096 (0.836-1.437) | 1.028 (0.742-1.426) | ||
| Lymphocytes (×109/L) | 0.003 | <0.001 | ||
| >2.10 | 1.000 | 1.000 | ||
| 1.60-2.10 | 1.403 (1.043-1.888) | 0.025 | 1.896 (1.307-2.752) | 0.001 |
| <1.60 | 1.646 (1.232-2.200) | 0.001 | 2.197 (1.525-3.164) | <0.001 |
| Monocytes (×109/L) | 0.474 | 0.816 | ||
| <0.40 | 1.000 | 1.000 | ||
| 0.40-0.50 | 1.033 (0.777-1.373) | 1.060 (0.759-1.482) | ||
| >0.50 | 1.176 (0.891-1.553) | 1.114 (0.799-1.554) | ||
| NLR | 0.003 | 0.003 | ||
| <1.62 | 1.000 | 1.000 | ||
| 1.62-2.40 | 1.223 (0.909-1.645) | 0.184 | 1.517 (1.061-2.169) | 0.022 |
| >2.40 | 1.618 (1.221-2.145) | 0.001 | 1.836 (1.297-2.598) | 0.001 |
| PLR | 0.021 | 0.009 | ||
| <81.62 | 1.000 | 1.000 | ||
| 81.62-111.00 | 1.207 (0.901-1.619) | 0.208 | 1.350 (0.946-1.925) | 0.097 |
| >111.00 | 1.488 (1.122-1.972) | 0.006 | 1.708 (1.214-2.402) | 0.002 |
| LMR | 0.001 | <0.001 | ||
| >4.80 | 1.000 | 1.000 | ||
| 3.50-4.80 | 1.223 (0.907-1.650) | 0.187 | 1.321 (0.916-1.906) | 0.137 |
| <3.50 | 1.671 (1.260-2.217) | <0.001 | 1.975 (1.403-2.779) | <0.001 |
Bold values represent that P were two-sided and P<0.05 was statistically significant.
Abbreviation: DFS, disease-free survival; CSS, cancer-specific disease HR: hazard ratio; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.